Modified t cells and methods of their use
AssigneeThe General Hospital Corporation
InventorMarcela V. MAUS
Life of this patent
Estimating the term…
Abstract
The technology described herein relates to modified T cells and their use in immunotherapeutic methods. In various examples, the T cells are modified so as to decrease or eliminate CD3ζ, TRAC, and/or TRBC expression.
Claims63
An isolated T lymphocyte modified to have reduced or eliminated expression of the T Cell Receptor (TCR), due to reduced or eliminated expression of a CD3ζ, T Cell Receptor Alpha Chain (TRAC), and/or T Cell Receptor Beta Chain (TRBC) gene, wherein the isolated T lymphocyte expresses a heterologous viral protein that facilitates the T lymphocyte in evading immune attack from a host to whom the T lymphocyte is administered, wherein the viral protein:
- (a) is not from cytomegalovirus (CMV), Epstein Barr virus (EBV), herpes simplex virus (HSV), or bovine herpes virus-1 (BoHV-1), or alternatively
- (b) is not CMV US6, HSV ICP47, BoHV-1 UL49.5, EBV BNLF2a, CMV UL40, CMV UL18, or CMV UL42.
A vector comprising a gene encoding a therapeutic protein and a heterologous viral protein that facilitates immune system evasion, wherein the heterologous protein:
- (a) is not from cytomegalovirus (CMV), Epstein Barr virus (EBV), herpes simplex virus (HSV), or bovine herpes virus-1 (BoHV-1), or alternatively
- (b) is not CMV US6, HSV ICP47, BoHV-1 UL49.5, EBV BNLF2a, CMV UL40, CMV UL18, or CMV UL42.
Dependencies are inferred from the claim text.